AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Pharma Newsmaker of the Year
In the second half of the year, you saw potentially big changes in how we treat depression. In December, Biogen and Stagioputics filed for approval for a neuroactive steroid for MDD as well as for postpartum depression. J&J got approval for S-ketamine back in 2019, which I think is still something of a niche product. It seems like the field will evolve considerably in coming years.